NCT00079716 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma


Sponsors: Seattle Genetics, Inc. Genentech	Phases: Phase I
Indications	Acronym:
Multiple Myeloma
Age Groups: Adult Senior	Gender: Both
Names: Drug: SGN-40 (anti-huCD40 mAb)	Enrollment: 44

Additional information about NCT00079716.